BeOne Medicines AG (BVMF:B1ME34)
Brazil · Delayed Price · Currency is BRL 66.50
0.00 (0.00%)
Last updated: Nov 11, 2025, 10:00 AM GMT-3
BeOne Medicines AG Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 4,998 | 3,810 | 2,459 | 1,416 | 1,176 | 308.87 | Upgrade | |
Revenue Growth (YoY) | 49.15% | 54.96% | 73.65% | 20.37% | 280.83% | -27.87% | Upgrade |
Cost of Revenue | 685.12 | 594.09 | 379.92 | 286.48 | 164.91 | 1,366 | Upgrade |
Gross Profit | 4,313 | 3,216 | 2,079 | 1,129 | 1,011 | -1,057 | Upgrade |
Selling, General & Admin | 2,049 | 1,832 | 1,509 | 1,279 | 990.12 | 600.18 | Upgrade |
Research & Development | 2,093 | 1,953 | 1,779 | 1,641 | 1,459 | - | Upgrade |
Amortization of Goodwill & Intangibles | - | - | - | - | 0.75 | 0.85 | Upgrade |
Operating Expenses | 4,128 | 3,785 | 3,287 | 2,919 | 2,450 | 601.02 | Upgrade |
Operating Income | 185.81 | -569.01 | -1,209 | -1,790 | -1,439 | -1,658 | Upgrade |
Interest Expense | -14.74 | -14.74 | -4.23 | -19.11 | -28.21 | -17.97 | Upgrade |
Interest & Investment Income | 40.23 | 62.57 | 78.24 | 71.59 | 12.45 | 19.97 | Upgrade |
Earnings From Equity Investments | -10.28 | -10.28 | -7.86 | -3.68 | -1.8 | -0.49 | Upgrade |
Other Non Operating Income (Expenses) | -13.24 | 7.35 | -39.49 | -195.13 | 8.31 | 25.5 | Upgrade |
EBT Excluding Unusual Items | 187.78 | -524.1 | -1,182 | -1,936 | -1,448 | -1,631 | Upgrade |
Gain (Loss) on Sale of Investments | -7.4 | -8.9 | -6.87 | -25.04 | 9.39 | 12.48 | Upgrade |
Gain (Loss) on Sale of Assets | -0.41 | - | - | - | - | - | Upgrade |
Other Unusual Items | - | - | 362.92 | - | - | - | Upgrade |
Pretax Income | 162.94 | -533 | -825.84 | -1,961 | -1,439 | -1,618 | Upgrade |
Income Tax Expense | 129.95 | 111.79 | 55.87 | 42.78 | 19.23 | 10.4 | Upgrade |
Earnings From Continuing Operations | 33 | -644.79 | -881.71 | -2,004 | -1,458 | -1,629 | Upgrade |
Minority Interest in Earnings | - | - | - | - | - | 3.62 | Upgrade |
Net Income | 33 | -644.79 | -881.71 | -2,004 | -1,458 | -1,625 | Upgrade |
Net Income to Common | 33 | -644.79 | -881.71 | -2,004 | -1,458 | -1,625 | Upgrade |
Shares Outstanding (Basic) | 108 | 105 | 104 | 103 | 93 | 83 | Upgrade |
Shares Outstanding (Diluted) | 112 | 105 | 104 | 103 | 93 | 83 | Upgrade |
Shares Change (YoY) | 7.42% | 0.86% | 1.22% | 11.15% | 11.16% | 38.99% | Upgrade |
EPS (Basic) | 0.31 | -6.12 | -8.45 | -19.43 | -15.71 | -19.47 | Upgrade |
EPS (Diluted) | 0.29 | -6.12 | -8.45 | -19.43 | -15.71 | -19.47 | Upgrade |
Free Cash Flow | 489.91 | -633.29 | -1,719 | -1,822 | -1,562 | -1,401 | Upgrade |
Free Cash Flow Per Share | 4.37 | -6.01 | -16.47 | -17.67 | -16.83 | -16.78 | Upgrade |
Gross Margin | 86.29% | 84.41% | 84.55% | 79.77% | 85.98% | - | Upgrade |
Operating Margin | 3.72% | -14.93% | -49.15% | -126.40% | -122.31% | -536.69% | Upgrade |
Profit Margin | 0.66% | -16.92% | -35.86% | -141.52% | -123.93% | -526.10% | Upgrade |
Free Cash Flow Margin | 9.80% | -16.62% | -69.93% | -128.68% | -132.76% | -453.57% | Upgrade |
EBITDA | 333.85 | -401.98 | -1,125 | -1,727 | -1,393 | -1,626 | Upgrade |
EBITDA Margin | 6.68% | -10.55% | -45.74% | -121.94% | -118.44% | - | Upgrade |
D&A For EBITDA | 148.04 | 167.03 | 83.94 | 63.05 | 45.49 | 31.79 | Upgrade |
EBIT | 185.81 | -569.01 | -1,209 | -1,790 | -1,439 | -1,658 | Upgrade |
EBIT Margin | 3.72% | -14.93% | -49.15% | -126.40% | -122.31% | - | Upgrade |
Revenue as Reported | 3,810 | 3,810 | 2,459 | 1,416 | 1,176 | 308.87 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.